BioGeometry is an AI-driven pharmaceutical company focused on developing next-generation, programmable protein medicines. The company leverages advanced technologies such as geometric deep learning, structural biology, immunology, and synthetic biology to create innovative treatments for oncology, autoimmune, and infectious diseases. BioGeometry aims to address the high costs, long lead times, and low success rates associated with traditional macromolecular therapeutics by utilizing artificial intelligence to design medicines. The company serves clients in the pharmaceutical and biotechnology sectors, offering solutions that expedite drug development processes and reduce costs. BioGeometry's business model revolves around the digitalization and automation of drug discovery, which allows for faster and more efficient development cycles. Revenue is generated through partnerships, licensing agreements, and the commercialization of proprietary medicines.

Keywords: AI-driven, biotech, programmable medicines, geometric deep learning, structural biology, immunology, synthetic biology, oncology, autoimmune diseases, infectious diseases.